This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Mitochondria; glycolysis	<p>Studies in cell culture suggest combining mitochondrial antioxidants and glycolysis inhibitors could help treat breast cancer. In cultured breast cancer cell lines, a combination of the glycolysis inhibitor 2-deoxyglucose (2-DG) and the mitochondria-targeted antioxidant compounds MitoQ or MitoCP decreased intracellular ATP levels, colony formation and cell survival compared with either treatment alone. Next steps include preclinical pharmacokinetic and safety studies. Antipodean Pharmaceuticals Inc.'s MitoQ is in Phase II testing for HCV. In 2011, Threshold Pharmaceuticals Inc. discontinued development of 2-DG, which was in Phase I testing for solid tumors.</p> <p>SciBX 5(18); doi:10.1038/scibx.2012.461 Published online May 3, 2012</p>	Patented; available for licensing	<p>Cheng, G. <i>et al. Cancer Res.</i>; published online March 19, 2012; doi:10.1158/0008-5472.CAN-11-3928 Contact: Balaraman Kalyanaraman, Medical College of Wisconsin, Milwaukee, Wis. e-mail: balarama@mcw.edu</p>